RxDoctor Payments Data

Stephen Bell, MD

Internal Medicine · Thomaston, GANPI 1821037433

Payments from drug & device makers

$1,744in general payments, 2019–2025

Across 102 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$433
  • Johnson & Johnson$285
  • GSK$138
  • Avanir Pharmaceuticals, Inc.$121
  • Baxter Healthcare$112
  • Novartis$91
  • plus $564 from 16 others

What the payments were for

  • Food & beverage$1,56089%
  • Education$151%
  • Other$16810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,744 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$31,573
Medicare patients
99
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$68,187
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$55,030
FarxigaDapagliflozin Propanediol58$44,236
LinzessLinaclotide53$32,468
OzempicSemaglutide22$29,010
RybelsusSemaglutide12$22,300
JanuviaSitagliptin Phosphate11$18,295
Tresiba Flextouch U-100Insulin Degludec23$15,366
JardianceEmpagliflozin11$13,999
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$13,805
MounjaroTirzepatide11$11,547
Tresiba Flextouch U-200Insulin Degludec13$8,053
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen295$7,905
Combivent RespimatIpratropium/Albuterol Sulfate14$6,847
Gabapentin450$5,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$68,187107 claims
GSKTrelegy Ellipta$138$55,03060 claims
Novo NordiskOzempic, Rybelsus$433$51,31034 claims
AstraZenecaFarxiga, Symbicort$62$47,42072 claims
AbbVieLinzess$35$32,46853 claims
Boehringer IngelheimJardiance, Combivent Respimat$60$20,84625 claims
Lilly USA, LLCMounjaro$60$11,54711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Thomaston

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →